Exploring New Possibilities for Eosinophilic Esophagitis (EoE) Treatment
Eosinophilic Esophagitis (EoE) is becoming an increasingly recognized health condition, with studies estimating its prevalence to be around 34.4 cases per 100,000 people worldwide (JAMA). Despite advancements in treatment, many individuals struggle with persistent symptoms, as the condition tends to return when therapies are stopped.
Researchers at the National Institutes of Health (NIH), led by Dr. Gregory Constantine from the National Institute of Allergy and Infectious Diseases (NIAID), are exploring a potential new option for managing EoE. They are conducting a study on Zemaira®, an FDA-approved medication, to determine its effectiveness in treating adults aged 18 to 70 who have been diagnosed with EoE.
Dr. Constantine emphasizes that targeted therapies focused on eosinophils, the white blood cells responsible for inflammation in EoE, have reshaped the way eosinophilic disorders are treated. This research offers an opportunity to delve deeper into how eosinophils function and their broader impact on the immune system.
Why Join This Study?
Participating in this study could provide valuable insights that may lead to better treatment approaches for EoE and related disorders in the future.
If you or someone you know has been diagnosed with EoE, consider taking part in this important research. For more details, visit the study website or contact the NIH Clinical Center Office of Patient Recruitment at 1-800-411-1222, referencing Study #001854-I.